Evidence map›Paper›PMID 34347848›Full record

ArticlePloS one2021

Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase.

Akira Madarame, Masakatsu Fukuzawa, Yoshiya Yamauchi, Shin Kono, Akihiko Sugimoto, Hayato Yamaguchi, Takashi Morise, Yohei Koyama, Kumiko Uchida, Maya Suguro and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Akira MadarameDepartment of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.ORCID 0000-0001-5876-2508
Masakatsu FukuzawaDepartment of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
Yoshiya YamauchiDepartment of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
Shin KonoDepartment of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
Akihiko SugimotoDepartment of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
Hayato YamaguchiDepartment of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
Takashi MoriseDepartment of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
Yohei KoyamaDepartment of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
Kumiko UchidaDepartment of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
Maya SuguroDepartment of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
Taisuke MatsumotoDepartment of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
Kagawa YasuyukiDepartment of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
Takashi KawaiDepartment of Gastroenterological Endoscopy, Tokyo Medical University Hospital, Tokyo, Japan.
Takao ItoiDepartment of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
Tokyo Medical University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesUseful indices to determine whether to reduce the dose of 5-aminosalicylic acid (5-ASA) in patients with ulcerative colitis (UC) during remission remain unclear. We aimed to analyze the rate and risk factors of relapse after reducing the dose of oral 5-ASA used for maintenance therapy of UC.

methodsUC patients whose 5-ASA dose was reduced in clinical remission (partial Mayo score of ≤ 1) at our institution from 2012 to 2017 were analyzed. Various clinical variables of patients who relapsed after reducing the dose of oral 5-ASA were compared with those of patients who maintained remission. Risk factors for relapse were assessed by univariate and multivariate logistic regression analyses. Cumulative relapse-free survival rates were calculated using the Kaplan-Meier method.

resultsA total of 70 UC patients were included; 52 (74.3%) patients maintained remission and 18 (25.7%) patients relapsed during the follow-up period. Multivariate analysis indicated that a history of acute severe UC (ASUC) was an independent predictive factor for clinical relapse (p = 0.024, odds ratio: 21, 95% confidence interval: 1.50-293.2). Based on Kaplan-Meier survival analysis, the cumulative relapse-free survival rate within 52 weeks was 22.2% for patients with a history of ASUC, compared with 82.0% for those without. the log-rank test showed a significant difference in a history of ASUC (p < 0.001).

conclusionsDose reduction of 5-ASA should be performed carefully in patients who have a history of ASUC.

Indexed as

Administration, OralAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalColitis, UlcerativeDrug TaperingFemaleFollow-Up StudiesHumansMaleMesalamineMiddle AgedPrognosisRecurrenceRemission InductionAnti-Inflammatory Agents, Non-SteroidalMesalamine

Identifiers

PMID34347848
PMCPMC8336875
OpenAlexW3188640808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.